LONDON, September 4, 2015 /PRNewswire/ --
Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines
Allergic Rhinitis drugs - new study showing you trends, partnerships, and predicted revenues
Where is the market for allergic rhinitis drugs heading? What are the commercial prospects for this market? Visiongain's new report shows you potential revenues and other trends to 2025, discussing data, opportunities and prospects.
Our 326 page report provides 273 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess:
• Forecasted sales at world market, submarket, regional and national level
• You will see financial results and revenue predictions
• Interviews, trends, opportunities
Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you will find:
• Original analyses, with business outlooks and developments
• Discover qualitative analyses (including SWOT and Porter's Five Forces)
• Company profiles and commercial developments
Read the full transcript of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
• Tonya Winders, President and CEO, Allergy & Asthma Network
• Amena Warner, Nurse Advisor at Allergy UK and President, International Nurses Group in Immunodeficiencies
• Dr Apelle Econs MRCS LRCP, Consultant - Allergy & Nutrition, Allergy Medical UK
You will find prospects for key submarkets
In addition to analyses of the overall world market, you will see revenue forecasting of five world-level submarkets to 2025:
• Oral antihistamines
• Intranasal corticosteroids
• Immunotherapy & Vaccines
• Intranasal antihistamines
• Other allergic rhinitis drugs
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
Additionally, our new study provides global sales forecasts by volume for the intranasal corticosteroids and intranasal antihistamines submarkets, including individual global sales forecasts by volume for the leading drugs in these submarkets from 2015-2025.
Our investigation shows business research and analysis with individual revenue forecasts and discussions for each submarket.
See revenue forecasts for products
How will leading drugs perform to 2025 at world level? Our study forecasts sales of 25 marketed products, including these brands:
• Claritin/ Claritin OTC
• Allegra/ Allegra-D/ Allegra OTC
• Staloral
• Ragwitek
• Nasonex
• Omnaris
• Patanase
• Astepro
• Clarinex
Discover how high revenues can go. You will see what's happening, understanding trends, challenges and opportunities.
What are the prospects for the leading regions and countries?
You will discover individual revenue forecasts for 12 leading national markets to 2025. There are many commercial opportunities to exploit in both developed and developing countries.
• US
• China
• Japan
• Germany
• India
• France
• UK
• Italy
• Spain
• Brazil
• Russia
• Mexico
• Rest of the World
Our analyses show that emerging economies, particularly in South America and Asia, will continue to achieve high revenue growth to 2025. Various economic, geographical, and regulatory factors globally will influence the market.
Leading companies and potential for market growth
We expect the rising prevalence and the consequent increase in demand for allergic rhinitis drugs, expanding healthcare coverage, the strength of the R&D pipeline and developments in drug delivery technologies to contribute to an increase in sales for allergic rhinitis drugs to 2025.
Our work shows you what organisations hold greatest potential. See profiles of 8 leading companies, including these:
• UCB
• Sanofi
• Kyowa Hakko Kirin
• GlaxoSmithKline
• ALK- Abelló
• Stallergenes
• Merck & Co
• Johnson & Johnson
A company profile gives you the following information:
• Revenue forecast for allergic rhinitis drugs from 2015 to 2025
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), and collaborations, including alliances, partnerships, and joint ventures
• Discussion of a company's activities and outlook
• Allergic rhinitis drugs revenue forecast from 2015 to 2025
Discover capabilities, progress, and commercial prospects, helping you stay ahead. What effects will regulatory changes have?
Research and development activities - assess innovation, trends and possibilities
What is happening in the R&D pipeline for allergic rhinitis treatments? You see developmental trends, gaining insight into each segment of the allergic rhinitis drug R&D pipeline for:
• Intranasal corticosteroids
• Immunotherapy
• Oral antihistamines
• Other progress in allergic rhinitis
Our study also discusses these agents and technologies, among others:
• Subcutaneous immunotherapy
• Sublingual immunotherapy tablets
• Oral antihistamines
• Intranasal corticosteroids
• Novel small molecules including toll-like receptor antagonists
What issues will affect the allergic rhinitis drugs market?
Our new report lets you assess industry trends and outlooks. Our study discusses issues affecting allergic rhinitis treatments. You will find discussions, including qualitative analyses:
• A strong immunotherapy R&D pipeline
• Patent expiries and generic competition
• Pricing and reimbursement pressures created by government cost-cutting initiatives
• Rx-to-OTC switching
• Growth areas such as in combination drugs and immunotherapy
• The changing socio-economic conditions impacting allergic rhinitis drug demand
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape
How the Allergic Rhinitis Drugs Market Forecast 2015-2025: Future Prospects for Companies in Antihistamines, Corticosteroids, immunotherapy & Vaccines report helps you
In summary our 326 page report gives you the following knowledge:
• Revenues to 2025 for the overall allergic rhinitis drugs market - discover the industry's prospects, finding promising areas for investments and revenues
• Revenue forecasts to 2025 for 5 product categories (therapeutic classes) within allergic rhinitis drugs - discover forecasts for intranasal antihistamines, oral antihistamines, immunotherapy & vaccines, intranasal corticosteroids and other allergic rhinitis drugs
• Revenue forecast to 2025 for 12 leading national markets - US, China, Japan, India, Germany, France, UK, Italy, Spain, Russia, Brazil, Mexico, and Rest of the World
• Assess leading companies - hear about the products, results and strategies, including recent activities, future outlook, and allergic drugs revenue forecast for 8 leading companies, including UCB, Stallergenes, Merck & Co, and Sanofi
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• Opinions from our survey, seeing interviews with industry authorities
• IP protection and generic drug competition - see what affects product revenue
You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain's study is for everybody needing commercial analyses for the allergic rhinitis drugs market and the leading companies within it. You will find data, trends and predictions. Please order our report now.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100
Or click on https://goo.gl/hB0Zdo
Companies Mentioned in the Report
ActoGeniX
Adamis Pharmaceuticals
Alergo Pharma
ALK- Abelló
Allergy Medical UK
Allergy Therapeutics
Almirall
Altana Pharma (Nycomed)
Ampio
Anergis
Apotex
Ares Life Sciences
Aspen Pharmacare
AstraZeneca
Atopix Therapeutics
Barr Laboratories
Bausch & Lomb
Belcher Pharmaceuticals
Biotech Tools
Catalent Pharma Solutions
Celsus Therapeutics
Circassia Pharmaceuticals
Dainippon Sumitomo
DBV Technologies
Dr Reddy's Laboratories
Eddingpharm
Eleventa
Fountain Biopharma
GenMont Biotech
Genzyme (Sanofi)
GlaxoSmithKline
GlycoMar Limited
Greer Laboratories
Hi Tech Pharma
Hisamitsu Pharmaceutical Co
Hoechst AG
Human Genome Sciences
Intas Pharmaceuticals
Johnson & Johnson
Kalypsys
Keldman Healthcare
Kyowa Hakko Kirin
Leti Pharma (Laboratorios Leti)
Lupin Pharmaceuticals
Meda Pharma
Medpointe Inc (Meda Pharma)
Merck & Co
Mitsubishi Tanabe Pharma
Mylan
Nektar Therapeutics
Nippon Paper Group
Novartis
Nuvo Research
Omega Pharma
Ono Pharmaceutical
Oxagen
Perrigo
Pfizer
ProStrakan (Kyowa Hakko Kirin)
Reckitt Benckiser
Roxane Laboratories (Boehringer Ingelheim)
Sanofi
Schering-Plough (Merck)
Shionogi & Co Ltd
Stallergenes
Sun Pharmaceuticals
Sunovion Pharmaceuticals (Dainippon Sumitomo)
Takeda
Teva Pharmaceuticals
Trimel Pharmaceuticals
Ube Industries
UCB
VentiRx
Verona Pharma
ViiV Healthcare
Wockhardt
Ziarco Pharma
Organisations Mentioned in the Report
Allergy & Asthma Network
AllergyUK
American Academy of Allergy, Asthma and Immunology (AAAAI)
British Society for Allergy & Clinical Immunology (BSACI) [UK]
Farmácia Popular [Brazil]
Imperial College London
International Nurses Group In Immunodeficiencies
Japanese Ministry of Health, Labour and Welfare
Les Entreprises Du Médicament (Leem) [France]
National Development and Reform Commission (NDRC) [China]
National Pharmaceutical Pricing Authority (NPPA) [India]
PollenUK
The Pharmaceutical Research and Manufacturers of America (PhRMA)
The UK Health and Social Care Information Centre
Université Libre de Bruxelles [Belgium]
University of Leuven [Belgium]
US Attorney's Office for the Eastern District of Pennsylvania
US Food and Drug Administration (FDA)
World Allergy Organisation
World Health Organisation (WHO)
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44(0)20-7336-6100
Or click on https://goo.gl/hB0Zdo
SOURCE Visiongain
